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The recognition of human papillomavirus (HPV) infection as a risk factor for the development of oropharyngeal squamous cell carcinoma was a substantial development in the field of head and neck oncology. HPV-positive oropharyngeal squamous cell carcinoma is widely considered a potential epidemic because of its rapidly increasing incidence. 1 Furthermore, HPV-positive oropharyngeal squamous cell carcinoma is an entirely distinct disease entity from HPV-negative oropharyngeal squamous cell carcinoma. 2 There are differences in the oncogenesis between these two entities, which mean a much younger, healthier patient population has HPV-positive oropharyngeal squamous cell carcinoma, which frequently does not have the risk factors associated with HPV-negative oropharyngeal squamous cell carcinoma. 3 Smoking, alcohol consumption, and the synergistic effect between the two are well recognised risk factors for development of HPV-negative oropharyngeal squamous cell carcinoma; however, these behaviours are in decline, which is reflected in the diminishing incidence of HPVnegative head and neck squamous cell carcinoma. 4 By contrast, the substantial increase in incidence of HPVpositive oropharyngeal squamous cell carcinoma has been attributed to a probable increase in HPV infection. This increase could be due to changes in sexual practices within the affected population during the past four decades. 1 HPV-positive oropharyngeal squamous cell carcinoma is more sensitive to chemotherapy and radiotherapy than is HPV-negative oropharyngeal squamous cell carcinoma, which translates to a much better prognosis with conventional treatment protocols in this group of patients. 1, 5, 6 Hence, HPV status is considered the most important prognostic indicator in head and neck oncology, reflected by the inclusion of p16 status in the eighth edition of the American Joint Committee on Cancer Staging System. 3, 6 However, traditional therapeutic interventions are associated with substantial morbidity and have a great impact on patient quality of life.
1 This impact is especially pertinent for patients with HPV-positive oropharyngeal squamous cell carcinoma because they are typically much younger and therefore have to live with the consequences of their treatment for far longer. These factors have led to the investigation of de-intensified therapies for patients with HPV-positive oropharyngeal squamous cell carcinoma. Various strategies have been considered, such as reduction in radiotherapy dose following induction chemotherapy, radiotherapy alone, minimally invasive surgical techniques, or substituting platinumbased chemotherapy with cetuximab. 2, 7, 8 In The Lancet, Hisham Mehanna and colleagues 9 report the outcome of their international, randomised controlled trial (De-ESCALaTE HPV), which investigated the substitution of cisplatin with cetuximab in patients with advanced HPV-positive oropharyngeal squamous cell carcinoma. 9 334 patients with low-risk (non-smoker or lifetime smoker with <10 pack-year smoking history) HPV-positive oropharyngeal squamous cell carcinoma were randomly assigned to receive either cisplatin or cetuximab in addition to a standardised radiotherapy treatment regimen. The authors considered the use of cisplatin as the standard of care and hence substitution with cetuximab could be considered deviation or de-escalation from the established standard. In this trial, 9 HPV-positive disease was established by use of p16 positivity as a surrogate marker and retrospective in-situ hybridisation analysis. This confirmation of HPV positivity combined with the inclusion of only lowrisk patients 10 represented a safe de-escalation trial design that selected patients with the most favourable prognosis. The primary outcome of this study was overall severe (grade 3-5) toxicity events, and secondary outcomes included overall survival, time to recurrence, quality of life, and swallowing outcomes. 9 Despite observing a significantly higher number of serious adverse events in the cisplatin group than in the cetuximab group, there was no difference in overall severe toxicity between the two groups. However, the spectrum of toxicity varied substantially between the two groups, with skin toxicity and infusion reactions more common in the cetuximab group and gastrointestinal and labyrinthine (otological symptoms including hearing loss, tinnitus, and vertigo) symptoms predominating in the cisplatin group. Equally, there was no difference between the groups in quality of life or swallowing outcomes. Far more concerning was the significant reduction in 2-year overall survival (97·5% vs 89·4%, hazard ratio [ 11 This difference between the two study designs might reflect regional practice patterns, with cisplatin commonly substituted for cetuximab in older patients, patients with poorer performance status, and those stratified as low risk in North America.
11
HPV-positive disease was established via the surrogate of p16 positivity and, in contrast to Mehanna and colleagues, 9 recruitment was not limited to low-risk patients.
11 849 patients were enrolled and randomly assigned to receive a standardised radiotherapy treatment regimen plus either cisplatin or cetuximab. After a median follow-up of 4·5 years, radiotherapy plus cetuximab did not meet the criteria for noninferiority for overall survival (HR 45·1, one-sided 95% upper CI 1·94; p=0·5056) and was associated with a 45% increased risk of death. Furthermore, the risks of cancer progression or death and locoregional failure were increased. Severe acute and late toxicity were similar between the cetuximab and cisplatin groups.
Although both Articles should be considered landmark studies in their own right, it is the harmonising findings that are most notable. The differing study designs and primary outcomes are complementary and serve to offset any substantial limitations of either study in isolation. Both trials showed that substitution of cisplatin with cetuximab resulted in significantly worse survival outcomes, without any difference in acute or late toxicity. The lack of efficacy of cetuximab in HPV-positive disease, 9,11 despite its well documented success in the management of HPV-negative head and neck squamous cell carcinoma, 12 might be related to the difference in epidermal growth factor receptor (EGFR) expression in HPV-negative versus HPV-positive oropharyngeal squamous cell carcinoma. Although HPV-negative head and neck squamous cell carcinoma is associated with overexpression of EGFR, there is evidence to suggest that an inverse association exists in HPV-positive oropharyngeal squamous cell carcinoma. 7 Cisplatin should be used as the radiosensitiser of choice in all eligible patients with advanced HPVpositive oropharyngeal squamous cell carcinoma. This recommendation is pertinent as there is emerging evidence showing a substantial increase in HPVpositive oropharyngeal squamous cell carcinoma in older patient groups (>70 years). 13 These results also serve as a timely reminder that although HPVpositive oropharyngeal squamous cell carcinoma has an excellent prognosis with existing well established treatment protocols, treatment de-intensification strategies should only be evaluated within the confines of well designed clinical trials.
